Article

IntraLens Vision changes name, revises strategy

Lake Forest, CA—IntraLens Vision Inc. has changed its name to ReVision Optics Inc. (RVO) to align with its strategy to enter the presbyopia market.

Lake Forest, CA-IntraLens Vision Inc. has changed its name to ReVision Optics Inc. (RVO) to align with its strategy to enter the presbyopia market.

"We feel our new name, ReVision Optics, perfectly suits both our corporate mission and our products," said J. Randy Alex-ander, ReVision Optics president. "ReVision Optics will be targeting the refractive surgery market with an emphasis on the surgical correction of presbyopia via an intracorneal lens."

Alexander added that IntraLase Corp. has agreed to develop specialized software that will enable ReVision Optics to develop the collateral products to move forward in the marketplace. The software will enable ReVision Optics to produce two types of customized flaps that will assist eye surgeons to easily inject the company's intracorneal lenses.

"While continuing to gain global market share of corneal flaps for LASIK, an integral part of our strategy is to also establish our laser as enabling technology for corneal applications, which include corneal inlays, rings, and therapeutic procedures," said Robert J. Palmisano, IntraLase president and chief executive officer.

As part of this agreement with ReVision, IntraLase will acquire full rights to the name IntraLens.

ReVision Optics will develop, manufacture, and market intracorneal lenses to correct and maintain vision. Its lenses are made from its proprietary microporous hydrogel material and will be trademarked under the name PresbyLens.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times Europe) Anat Loewenstein, MD, shares insights on the real-world results of remote retinal imaging
(Image credit: Ophthalmology Times) Two-wavelength autofluorescence for macular xanthophyll carotenoids with Christine Curcio, PhD
(Image credit: Ophthalmology Times) FLIO and the brain: Making the invisible visible with Robert Sergott, MD
(Image credit: Ophthalmology Times) Structure-function correlates using high-res OCT images with Karl Csaky, MD, PhD
(Image credit: Ophthalmology Times) SriniVas Sadda, MD, on high-res OCT of atrophic and precursor lesions in AMD
(Image credit: Ophthalmology Times) Christine Curcio, PhD, shares histology update supporting review software and revised nomenclature for <3 μm OCT
1 expert is featured in this series.
1 expert is featured in this series.
1 expert is featured in this series.
© 2025 MJH Life Sciences

All rights reserved.